Experience in production of 68Ga-DOTA-NOC for clinical use under an Expanded Access IND

Mark A. Green, Carla J. Mathias, James W. Fletcher

Research output: Contribution to journalArticle

3 Scopus citations


[68Ga]Ga-DOTA-NOC was produced under an Expanded Access IND for 174 clinical PET/CT studies to evaluate patients with neuroendocrine tumors. Production employed either the TiO2-based Eckert & Ziegler (EZAG) 68Ge/68Ga-generator (with fractionated elution), or the SiO2-based ITG 68Ge/68Ga-generator. In both cases, [68Ga]Ga-DOTA-NOC was reliably produced, without pre-synthesis purification of the 68Ga generator eluate, using readily-implemented manual synthesis procedures. [68Ga]Ga-DOTA-NOC radiochemical purity averaged 99.2±0.4%. Administered 68Ga dose averaged 181±22 MBq, and administered peptide mass averaged 43.2±5.2 µg (n=47) and 23.9±5.7 µg (n=127), respectively, using the EZAG and ITG generators. At dose expiration, 68Ge breakthrough in the final product averaged 2.7×10−7% and 5.4×10−5% using the EZAG and ITG generators, respectively.

Original languageEnglish (US)
Pages (from-to)63-68
Number of pages6
JournalApplied Radiation and Isotopes
StatePublished - Oct 1 2016


  • Expanded Access IND
  • Neuroendrocrine tumors
  • Positron emission tomography (PET)
  • Somatostatin receptor
  • [68Ga]Ga-DOTA-NOC

ASJC Scopus subject areas

  • Radiation

Fingerprint Dive into the research topics of 'Experience in production of <sup>68</sup>Ga-DOTA-NOC for clinical use under an Expanded Access IND'. Together they form a unique fingerprint.

Cite this